Nurix Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 61.47 | -100% | -11.72 | -100% |
| P/S |
|
4.09 | 33.58 | -87.81% |
|
|
| P/BV |
|
1.57 | 4.79 | -67.2% |
|
|
| P/FCF |
|
-5.13 | 61 | -108.42% |
|
|
| Ev/Ebitda |
|
-2.06 | -17.26 | -88.07% |
|
|
| Ev/S |
|
3.78 | 22.5 | -83.19% |
|
|
| Ev/FCF |
|
-3.24 | 69 | -104.7% |
|
|
| E/P |
|
-0.3124 | 0.0178 | -1857.65% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-183.68 | 4.97 | -3794.22% | -291.31 | -36.95% |
| ROE |
|
-71.8 | 9.61 | -846.98% |
|
|
| ROA |
|
-39.49 | 0.3443 | -11570.33% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
-186.98 | -25.17 | 642.87% |
|
|
| ROCE |
|
-77.34 | 15.19 | -609.29% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.2165 | -3.67 | -94.1% | -0.167 | +29.6% |
| Nеt Debt/Ebitda |
|
0.1698 | -4.06 | -104.19% |
|
|
| Debt/Ratio |
|
0.084 | 0.199 | -57.8% |
|
|
| Debt/Equity |
|
1.78 | 1.54 | 15.35% |
|
|
| Debt/Net Income |
|
-0.2127 | 10.34 | -102.06% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5399 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2256 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9598 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4928 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5399 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
147.43 | 76.2 | 93.48% | ||
| Growth impulse Ebitda in 5 years |
|
611.24 | 44.75 | 1265.9% | ||
| Growth impulse Net Income in 5 years |
|
563.39 | -15.36 | -3767.9% | ||
| Growth impulse FCF in 5 years |
|
8449.14 | -108.72 | -7871.47% | ||
| Growth impulse EPS in 5 years |
|
153.67 | -142.05 | -208.18% |
IP Score
4.91/10
